ISSN:2167-7964

Journal of Radiology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Conference Proceeding   
  • OMICS J Radiol , Vol 10(1)

Transition metal complexes/organometallic compounds as anticancer/anti HIV drugs or in pharmaceutical industry

Prakash Kinthada Kinthada*
Professor in Chemistry, India
*Corresponding Author: Prakash Kinthada Kinthada, Professor in Chemistry, India

Received: 09-Jan-2021 / Accepted Date: 21-Jan-2021 / Published Date: 27-Jan-2021

Abstract

Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoid, belonging to a group of flavonol, Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers. Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian System of medicine. We provide a summarized synthesis and structural determination of Curcumin Oxime, Curcumin Thiosemicarbazone derivative of Gold (III) complex. The use of these analogs for prevention of cancer tumor progression and treatments of human malignancies. A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Au (III) complex and other complexes of Platinum, Palladium, Ruthenium, Copper etc . The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs. The main aim of our research is Design, Development and Synthesis of Transition Metal Complexes/Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to initiation of clinical trials.

Biography

I am Prof. Dr. Prakash. M. M. S Kinthada, a Professor in the Department of Chemistry at Sri Vidyanikethan Engineering college, Jawahar Lal Technological University, Anantapur, A. Rangam Peta, Tirupathi, INDIA. Earlier I was an Associate Professor in Chemistry, GIT, GITAM University, Visakhapatnam, INDIA. Ihave recently returned from USA, where I was a NIH visiting fellow atKARMONAS CANCER RESEARCH INSTITUTE, Wayne State University School of Medicine. Earlier I was a Royal Society Visiting Scientist in theInorganic chemistry laboratories at the University of Oxford, UK, working on” Transition metal complexes as Anticancer Drugs”. Earlier I was a visiting fellow at the Department of Chemical Engineering and Applied Chemistry at Aston University, Birmingham. Prior to that I was a Nehru Centenary British Council Fellow in the organometallic laboratories at Imperial college of Science, INDIA.

Abstract citation: Prakash Kinthada Professor in Chemistry, India; CancerStemcell 2020, Webinar On cancer stem cell and oncology research; August 24-25, 2020.

Conference: EuroScicon Conference on Cancer Stem Cell and Oncology Research: August 24-25, 2020.

Citation: Kinthada P (2021) Transition metal complexes/organometallic compounds as anticancer/anti HIV drugs or in pharmaceutical industry. J Entrepren Organiz Manag 10: e116.

Copyright: © 2021 Kinthada P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top